文献速递临床免疫分子诊断

整合IgG与IgA自身抗体用于肝细胞癌早期诊断

Integration of IgG and IgA autoantibodies for early diagnosis of hepatocellular carcinoma.
PubMed 文献 · Clin Chim Acta · 2021-10-30

本研究用ELISA法在380份回顾性血清样本中评估抗p53、CTAG1A、TIF1γ-IgG和抗TIF1γ-IgA四种自身抗体对早期肝细胞癌(HCC)的诊断价值,训练集构建预测模型并在独立验证集验证。四抗体联合面板在训练集AUC达0.814(95%CI 0.760-0.860),验证集AUC为0.824,提示该面板有助于早期HCC诊断。

要点

  • 抗p53-IgG在四种自身抗体中AUC最高(0.679),为优选标志物。
  • 四抗体联合面板诊断早期HCC的AUC在训练集为0.814,验证集为0.824。
  • 早期HCC组四种自身抗体水平和阳性率显著高于良性肝病组和健康对照组(P < 0.01)。

核心结论

  • 抗p53、CTAG1A和TIF1γ的血清IgG自身抗体及抗TIF1γ-IgA对早期HCC具有诊断价值。
  • 抗p53-IgG是较优选的生物标志物,四抗体联合面板可能有助于早期HCC诊断。

研究设计与样本

  • 采用ELISA法评估四种自身抗体,使用380份回顾性血清样本。
  • 训练集包括92例早期HCC、72例肝脏良性病变(HBL)和86例健康对照(HC),用于开发早期HCC预测模型。
  • 独立验证集数据用于评估和验证预测模型区分早期HCC与对照(HBL+HC)的性能。

主要发现

  • 训练集结果显示早期HCC组四种自身抗体水平和阳性率显著高于HBL组和HC组(P < 0.01)。
  • 抗p53-IgG的AUC最高为0.679,在93.7%特异性下敏感性为33.7%。
  • 四抗体联合面板在训练集所有可能组合中AUC最高,达0.814(95%CI 0.760-0.860),在84.2%特异性下敏感性为72.8%。
  • 该四抗体面板在验证集中AUC为0.824,在84.2%特异性下敏感性为70.8%。

关键数值与推荐

  • 抗p53-IgG:AUC 0.679,特异性93.7%时敏感性33.7%。
  • 四抗体联合面板:训练集AUC 0.814(95%CI 0.760-0.860),特异性84.2%时敏感性72.8%。
  • 四抗体联合面板:验证集AUC 0.824,特异性84.2%时敏感性70.8%。

临床怎么用

  • 可考虑检测血清抗p53-IgG、CTAG1A、TIF1γ-IgG和抗TIF1γ-IgA辅助早期HCC诊断。
  • 四抗体联合面板或可提高早期HCC的检出能力,但需结合临床和其他检查综合判断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Autoantibodes against tumor-associated antigens (TAAs) have been recommended for the early diagnosis of malignancies. In this study, we intend to comprehensively evaluate the performances of four autoantibodies including anti-p53, CTAG1A, TIF1γ-IgG and anti-TIF1γ-IgA for the early diagnosis of hepatocellular carcinoma (HCC), and then determine an optimal panel of autoantibodies for early HCC diagnosis. METHODS: The performances of four autoantibodies were evaluated by enzyme-linked immunosorbent assay (ELISA) for the early diagnosis of HCC with 380 retrospective serum samples. A training set comprised of 92 patients with early HCC, 72 patients with hepatic benign lesions (HBL), and 86 healthy controls (HC) was used to develop the predictive model for early HCC. And then, data obtained from an independent validation set was applied to evaluate and validate the predictive model to distinguish the early HCC from the controls (HBL + HC). RESULTS: The results of the training set showed the levels and positive rates of four autoantibodies in early HCC group were significantly higher than that in HBL group/HC group (P < 0.01), of which anti-p53-IgG exhibited the highest AUC of 0.679, with 33.7% sensitivity at 93.7% specificity; the panel comprised of four autoantibodies showed the highest AUC for the patients with early HCC, up to 0.814 (95%CI 0.760-0.860), with 72.8% sensitivity at 84.2% specificity among all possible combinations of four autoantibodies. Additionally, this four-autoantibody panel showed the AUC of 0.824, 70.8% sensitivity at 84.2% specificity in the validation set. CONCLUSIONS: Serum IgG autoantibodies against p53, CTAG1A and TIF1γ, and IgA autoantibody against TIF1γ present the diagnostic value for early HCC, of which anti-p53-IgG is a preferable biomarker. The panel comprised of four autoantibodies might contribute to early HCC diagnosis.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Yang T, Lin X, Zhang L, et al. Integration of IgG and IgA autoantibodies for early diagnosis of hepatocellular carcinoma. Clin Chim Acta. 2021. PMID: 34728178. doi:10.1016/j.cca.2021.10.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。